Search

Fred H Mermelstein

from West Newton, MA
Age ~65
Get Report
Also known as:
Fred H Memelstein, Fred N
Phone and address:
30 Colbert Rd, Newton, MA 02465
(617) 969-2477
Related to:
Mermelstein Akiva, 38
Connected to:
Alexander Y Mermelstein, 89Aron Mermelstein, 72Dee R Mermelstein, 75Gilad Mermelstein, 58Irene Mermelshtein, 70Magda Mermelstein, 106Moshe Mermelstein, 52Tova Mermelstein, 54Besnah Mermerian, 80Mathew S Mermigousis, 52

Fred Mermelstein Phones & Addresses

  • 30 Colbert Rd, West Newton, MA 02465 (617) 969-2477
  • 145 Paulson Rd, Waban, MA 02468
  • Newton, MA
  • 64 Dryden Rd, Montclair, NJ 07043 (973) 746-9388
  • 8 Skyview Ter, Clifton, NJ 07013 (973) 345-8858
  • West Caldwell, NJ
  • Hoboken, NJ
  • Highland Park, NJ
  • 64 Dryden Rd, Montclair, NJ 07043 (609) 922-6858

Work

Position: Production Occupations

Education

Degree: Associate degree or higher

Resumes

Resumes

Fred Mermelstein Photo 1

Director And Founder

View page
Location:
West Newton, MA
Industry:
Marketing And Advertising
Work:
Leviathan 2010 - 2010
Principal
Javelin Pharmaceuticals 2010 - 2010
Director and Founder
Pear Tree Pharmaceuticals 2010 - 2010
Chairman
Javelin Agency 2010 - 2010
Director and Founder
Education:
Rutgers Robert Wood Johnson Medical School 1986 - 1991
Rutgers University 1986 - 1991
Doctorates, Doctor of Philosophy
Skills:
Cloud Computing
Fred Mermelstein Photo 2

Member

View page
Location:
30 Colbert Rd east, Newton, MA 02465
Industry:
Pharmaceuticals
Work:
Leviathan 2010 - 2011
Partner
Redeem 2000 - 2005
Fred
IDDS - Greater New York City Area 1901 - 2001
Former CEO
Skills:
Start Ups
Pharmaceutical Industry
Strategic Planning
Strategy
Biotechnology
Business Strategy
Entrepreneurship
Mergers and Acquisitions
Venture Capital
Competitive Analysis
Leadership
Business Planning
Strategic Partnerships
Business Development
Marketing Strategy
Negotiation
Cross Functional Team Leadership
Fred Mermelstein Photo 3

Fred Mermelstein

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Fred H. Mermelstein
Director
Javelin Pharmacy
Ret Drugs/Sundries
125 Cambridgepark Dr, Cambridge, MA 02140
Fred H. Mermelstein
President
INNOVATIVE DRUG DELIVERY SYSTEMS, INC
Mfg Pharmaceutical Preparations
130 W 42 St, New York, NY 10036
130 W 42 St 12, New York, NY 10036
Fred Mermelstein
President
BYMER, INC
951 SW 4 Ave, Boca Raton, FL 33432
30 Colbert Rd, West Newton, MA 02465
Fred H. Mermelstein
Principal
Bymer, Inc
Business Consulting Services
145 Paulson Rd, Newton, MA 02468
Fred Mermelstein
Director, Chairman of the Board
PEAR TREE PHARMACEUTICALS, INC
Mfg and Dev Pharmaceutical Preparations
275 Grv St SUITE 2-400, Auburndale, MA 02466
West Newton, MA 02465

Publications

Us Patents

Compositions And Methods For The Treatment Of Primary And Metastatic Neoplastic Diseases Using Arsenic Compounds

View page
US Patent:
7132116, Nov 7, 2006
Filed:
Aug 14, 2003
Appl. No.:
10/640403
Inventors:
Ralph M. Ellison - Palm Beach FL, US
Fred H. Mermelstein - Clifton NJ, US
Assignee:
PolaRx Biopharmaceuticals Inc. - Wilmington DE
International Classification:
A01N 59/22
US Classification:
424623, 514615, 514733, 514908, 600 1
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Compositions And Methods For The Treatment Of Primary And Metastatic Neoplastic Diseases Using Arsenic Compounds

View page
US Patent:
7163703, Jan 16, 2007
Filed:
Aug 14, 2003
Appl. No.:
10/640399
Inventors:
Ralph M. Ellison - Palm Beach FL, US
Fred H. Mermelstein - Clifton NJ, US
Assignee:
PolaRx Biopharmaceuticals, Inc. - Wilmington DE
International Classification:
A61K 33/36
A61K 33/24
A61K 9/00
A61K 31/28
A61K 31/282
A61K 31/555
A61K 38/19
A61K 31/33
A61K 31/704
A61K 31/7048
A61K 31/7072
A61P 35/00
A61P 35/02
US Classification:
424623, 424 851, 4241841, 4242771, 4242781, 424620, 424629, 424649, 600 1, 514 2, 514 8, 514 12, 514 21, 514 23, 514 25, 514 27, 514 28, 514 29, 514 31, 514 34, 514 45, 514 49, 514 50, 514 90, 514109, 514110, 514171, 514183, 514184, 514185, 514249, 514251, 514274, 514283, 514444, 514449, 514492, 514504, 514559, 514575, 514588, 514615, 514733, 514908
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Nmda Receptor Antagonist Formulation With Reduced Neurotoxicity

View page
US Patent:
7273889, Sep 25, 2007
Filed:
Sep 25, 2002
Appl. No.:
10/256283
Inventors:
Fred H. Mermelstein - Upper Montclair NJ, US
Randi Albin - North Bergen NJ, US
Assignee:
Innovative Drug Delivery Systems, Inc. - New York NY
International Classification:
A61K 31/137
US Classification:
514650, 514657, 514665
Abstract:
The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.

Formulations Of Low Dose Diclofenac And Beta-Cyclodextrin

View page
US Patent:
8580954, Nov 12, 2013
Filed:
Mar 22, 2007
Appl. No.:
11/689931
Inventors:
Curtis Wright - Rockport MA, US
Daniel B. Carr - Chestnut Hill MA, US
Fred H. Mermelstein - Newton MA, US
Assignee:
Hospira, Inc. - Lake Forest IL
International Classification:
C07H 15/04
C07H 3/06
C08B 37/10
C08B 37/16
US Classification:
53612312
Abstract:
The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.

Compositions And Methods For The Treatment Of Primary And Metastatic Neoplastic Diseases Using Arsenic Compounds

View page
US Patent:
20020183385, Dec 5, 2002
Filed:
Oct 15, 1998
Appl. No.:
09/173531
Inventors:
Ralph Ellison - Palm Beach FL, US
Fred Mermelstein - Clifton NJ, US
International Classification:
A61K031/285
A61K033/00
US Classification:
514/504000, 424/623000
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Method For Treating Cancer

View page
US Patent:
20030036513, Feb 20, 2003
Filed:
Aug 26, 2002
Appl. No.:
10/228644
Inventors:
Edward Yurkow - Hillsborough NJ, US
Fred Mermelstein - Upper Montclair NJ, US
International Classification:
A61K038/17
A61K031/00
US Classification:
514/012000
Abstract:
A method of treating lymphoma, ovarian cancer, colorectal cancer, or gastric cancer by administering an effective amount of Mesna to a patient is provided. A method for treating and reducing the effective dose of an anti-cancer agent by administering Mesna in conjunction with an anti-cancer agent is also provided.

Compositions And Methods For The Treatment Of Primary And Metastatic Neoplastic Diseases Using Arsenic Compounds

View page
US Patent:
20040096518, May 20, 2004
Filed:
Nov 3, 2003
Appl. No.:
10/698625
Inventors:
Ralph Ellison - Palm Beach FL, US
Fred Mermelstein - Clifton NJ, US
Assignee:
PolaRx Biopharmaceuticals, Inc.
International Classification:
A61K038/19
A61K033/24
US Classification:
424/623000, 424/649000, 514/008000, 514/027000, 424/277100, 514/109000, 514/034000, 514/050000, 424/085100, 514/449000, 514/269000, 600/001000, 514/559000, 514/575000
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.

Nmda Receptor Antagonist Formulation With Reduced Neurotoxicity

View page
US Patent:
20040138298, Jul 15, 2004
Filed:
Dec 5, 2003
Appl. No.:
10/729869
Inventors:
Fred Mermelstein - Upper Montclair NJ, US
Randi Albin - North Bergen NJ, US
Assignee:
Innovative Drug Delivery Systems, Inc. - New York NY
International Classification:
A61K031/55
US Classification:
514/474000, 514/220000, 514/568000
Abstract:
The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and non-neurotoxic compounds having preservative activity for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The non-neurotoxic compound is selected from one of the following groups including organic acids, esters thereof, and salts thereof; alcohols, polyols, and phenols; alkyl parabens; cresols; benzalkonium chloride quaternary ammonium salts; chlorhexidine, imidurea, alpha tocopherol, and EDTA. Preferably, the nonneurotoxic compound is benzalkonium chloride, benzyl alcohol or phenol.
Control profile
Fred H Mermelstein from West Newton, MA, age ~65 Get Report